The leadership of Bladder Cancer has disclosed the following information in keeping with the journal's disclosure policy.
Seth P. Lerner, MD, Editor-in-Chief
Advisory Board: FerGene, Pfizer
Consultant: Genentech, UroGen, Vaxiion, Merck, QED Therapeutics, Verity
Clinical Trials: Genentech (SWOG), UroGen, Vaxiion, Endo, FKD, JBL (SWOG), Viventia
Licenses/Patents: TCGA Classifier
Other: UroToday (honoraria), IOS Press (editorial responsibilities, compensated), co-editor bladder cancer section UpToDate
Dan Theodorescu, MD, PhD, Editor-in-Chief
Consultant: Machavert, Merck, Urogen
Honoraria: Machavert, Merck, Urogen
Licenses/Patents: University of Colorado
Research Support: None
Stockholder in: None
Other: IOS Press (editorial responsibilities, compensated)
Hikmat A. Al-Ahmadie, MD, Associate Editor
Consultant: AstraZeneca, Paige.AI
Andrea B. Apolo, MD, Associate Editor
Nothing to disclose
Piyush K. Agarwal, MD, Associate Editor
Advisory Board (unpaid): AstraZeneca
Advisory Board (paid): AURA, Verity
Rebecca Barasky, MPH, Associate Editor
Nothing to disclose
Joaquim Bellmunt, MD, PhD, Associate Editor
Consultant or Advisory Role: Pierre Fabre, Astellas Pharma, Pfizer, Merck, Genentech, Novartis, AstraZeneca/MedImmune, Bristol-Myers Squibb
Research Funding: Millennium, Sanofi, Pfizer/EMD Serono
Stocks: Rainier
Travel, Accommodations, Expenses: Pfizer, MSD Oncology, Ipsen
Karim Chamie, MD, Associate Editor
Consultant: Urogen Pharma, ImmunityBio
Research Funding: Urogen Pharma, Merck
Speaker: BMS
Advisory Board: Urogen Pharma, BMS, ImmunityBio
David J. DeGraff, PhD, Associate Editor
Nothing to disclose
Lars Dyrskjøt, PhD, Associate Editor
Consultant: Ferring
Clinical Trials: Roche
Other Research Support: C2i Genomics, Natera, Ferring, AstraZeneca
Speaker Honoraria: Roche
Jason A. Efstathiou, MD, PhD, Associate Editor
Consultant: Blue Earth Diagnostics, Boston Scientific, AstraZeneca
Scientific Advisory Board: Merck, Myovant Sciences, Roivant Pharma, Progenics, Janssen
Bishoy M. Faltas, MD, Associate Editor
Honoraria: Springer Nature, UroToday
Clinical Trials: Eli-Lilly
Thomas Flaig, MD, Associate Editor
Consultant: Seattle Genetics, Janssen Oncology
Clinical Trials: Novartis,Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol-Myer's Squibb, Seattle Genetics, Merck, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, Tokai Pharmaceuticals, AstraZeneca/MedImmune, Lilly, Astellas Pharma, Agensys, La Roche-Posay
Other: Leadership: Aurora Oncology
Licenses/Patents: University of Colorado - 2 bladder cancer therapeutics (not in clinical trial)
Stockholder: Aurora Oncology
Georgios Gakis, MD, FEBU, Associate Editor
Advisory Board: MSD, Astellas, Ferring, BMS, Bayer, Leo Pharma, medac, Merck
Speaker Honoraria/Travel Grants: Roche, MSD, IPSEN, Erbe, medac
Donna Hansel, MD, PhD, Associate Editor
Consultant: AstraZeneca, Merck, Janssen
Other Research Support: Konica Minolta
Other: Genentech, AstraZeneca, Taris
Arndt Hartmann, MD, Associate Editor
Advisory Board: BMS, MSD, Roche, Cepheid, Qiagen, Janssen, Astra Zeneca, Agilent, Lilly, Phäon
Consultant: BMS, MSD, Roche, Astra Zeneca, Novartis, Boehringer Ingelheim, Abbvie, Cepheid, Nanostring, Illumina, Qiagen, Biontech, Janssen, 3D Histotech, Diaceutics
Clinical Trials: Janssen, Cepheid, AstraZeneca, Roche
Speaker Honoraria: BMS, MSD, Roche, Astra Zeneca, Boehringer Ingelheim, Abbvie, Janssen, Pfizer
Other Research Support: Illumina, Cepheid, Biotech, Roche, Janssen, Nanostring AstraZeneca
Anne Kiltie, MA, DM, DSc, Associate Editor
Research Grant Funding: CRUK, UCARE
Nathan Lawrentschuk, MD, PhD, Associate Editor
Clinical Education: Device Technologies Australia (robotic surgery)
Consultant: Boston Scientific
Research Funding: Astra Zeneca
Yair Lotan, MD, Associate Editor
Consultant or Advisory Role: C2I genomics (started Oct 2020), Photocure, Astra-Zeneca, Merck, Fergene, Abbvie (started Oct 2020), Cleveland Diagnostics, Nucleix, Ambu, Seattle Genetics (agreement Dec 2020), Hitachi (Jan 2020), Ferring Research (Feb 2020), verity pharmaceuticals
Clinical Trial or Scientific Study: Abbott (completed Mar 2019), Cepheid, Pacific Edge, FKD (completed 2019), MDxHealth, Biocancell (ended Jan 2020), GenomeDx Biosciences, Inc., Storz
Leadership: Vessi Medical, CAPs Medical
S. Bruce Malkowicz, MD, Associate Editor
Consultant: Pacific Edge
Clinical Trial Investigator: Merck
Surena F. Matin, MD, Associate Editor
Speaker: Ology Education, Urogen (ended Sep 2020)
Consultant: Urogen (ended Sep 2020), Simon, Kucher and partners (ended Jan 2020)
David McConkey, PhD, Associate Editor
Grant Support: Astra-Zeneca, Rainier Pharmaceuticals
Honoraria: Janssen, H3 Biomedicine, Rainier Pharmaceuticals
Edward M. Messing, MD, Associate Editor
Nothing to disclose
Matt Milowsky, MD, Associate Editor
Research Funding: Merck, Roche/Genentech, Bristol-Myers Squibb, Astellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, AstraZeneca, Mirati Therapeutics, Constellation Pharmaceuticals, Syndax, Incyte, Seagen, Amgen, Regeneron, Arvinas, Pfizer, Innocrin, Johnson & Johnson
Consultant (honoraria paid to institution): Asieris
Valeria Panebianco, MD, Associate Editor
Nothing to disclose
Francisco X. Real, MD, PhD, Associate Editor
Research Funding: Janssen
Bas W.G. van Rhijn, MD, PhD, Associate Editor
European Advisory Board Meeting: Ferring on trials in NMIBC (Dec 2018, Amsterdam, NL)
Scientific Advisory Committee: QED Therapeutics (2020)
Gottfrid Sjödahl, PhD, Associate Editor
Nothing to disclose
Mark S. Soloway, MD, Associate Editor
Nothing to disclose
Cora N. Sternberg, MD, Associate Editor
Consultant: Pfizer, Merck, AstraZeneca, Astellas Pharma, Sanofi-Genzyme, Roche/Genentech, Incyte, Medscape, Immunomedics, Clovis Oncology, UroToday, MSD
George Thalmann, MD, Associate Editor
Nothing to declare
Xue-Ru Wu, MD, Associate Editor
Nothing to disclose
Alexandre R. Zlotta, MD, PhD, Associate Editor
Consultant: AstraZeneca, Ferring, Janssen, Sanofi, Verity Pharma, Merck
Last updated: Feb 23, 2023
